MHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation
Martine E.D. Chamuleau(Dutch Cancer Society), Arjan A. van de Loosdrecht(Amsterdam UMC Location Vrije Universiteit Amsterdam), G.J. Ossenkoppele(Amsterdam UMC Location Vrije Universiteit Amsterdam)
Cited by 57
Related Papers
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
|The Lancet|2021|337